Cleveland BioLabs, Inc. (CBLI) financial statements (2020 and earlier)

Company profile

Business Address 73 HIGH STREET
BUFFALO, NY 14203
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:2334578
Cash and cash equivalents1234445
Short-term investments0011133
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)(0)(0)(0)(0)0
Receivables0000000
Other current assets0000000
Other undisclosed current assets000000(0)
Total current assets:2344678
Noncurrent Assets
Property, plant and equipment0000000
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:2345678
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111112
Accounts payable0000000
Accrued liabilities0111111
Derivative instruments and hedges, liabilities0000001
Total current liabilities:1111222
Noncurrent Liabilities
Liabilities, other than long-term debt   0   
Other liabilities   0   
Other undisclosed noncurrent liabilities 00 0  
Total noncurrent liabilities: 0000  
Total liabilities:1111222
Stockholders' equity
Stockholders' equity attributable to parent(3)(3)(2)(1)(1)01
Common stock0000000
Additional paid in capital163163163163163163163
Accumulated other comprehensive loss(1)(1)(1)(1)(1)(1)(1)
Accumulated deficit(166)(166)(165)(164)(164)(163)(162)
Stockholders' equity attributable to noncontrolling interest5555555
Total stockholders' equity:2234456
TOTAL LIABILITIES AND EQUITY:2345678

Income statement (P&L) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Revenue, net00000
Gross profit:0000000
Operating expenses(1)(1)(1)(1)(2)(1)(2)
Operating loss:(1)(1)(1)(1)(1)(1)(2)
Nonoperating income (expense)00(0)0001
Other nonoperating income (expense)00(0)0000
Net loss:(0)(1)(1)(0)(1)(1)(1)
Net income attributable to noncontrolling interest0000000
Net loss available to common stockholders, diluted:(0)(1)(1)(0)(1)(1)(1)

Comprehensive Income ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(0)(1)(1)(0)(1)(1)(1)
Other undisclosed comprehensive income (loss)(0)00(0)(0)(0)0
Comprehensive loss:(0)(1)(1)(0)(1)(1)(1)
Comprehensive income, net of tax, attributable to noncontrolling interest0000000
Comprehensive loss, net of tax, attributable to parent:(0)(1)(1)(0)(1)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: